Drug news
NICE rejects Scenesse as not cost effective
The National Institute for Health and Care Excellence (NICE) has in preliminary guidance rejected Scenesse (afamelanotide) a dissolving implant from Clinuvel Pharma, to treat erythropoietic protoporphyria, an inherited disorder affecting some 500-600 patients in England. NICE considered that the benefit of Scenesse was unclear from the evidence and that the product was not cost effective.